Interestingly, these results might also suggest that the blockade of NKG2A can not only potentiate the NK and CD8 natural cytotoxicity, but also improve NKs’ ability to kill tumor cells via their potent CD16-mediated ADCC activity when using tumor antigen-specific therapeutic antibodies. Here, KLRC1 is linked to neoplasm.